Cipla inks licensing pact with Novartis to manufacture, mkt diabetes drug ...Middle East

Drug major Cipla on Monday said it has inked a licensing pact with Novartis Pharma AG to manufacture and market Galvus range, used in the treatment of type 2 diabetes, from January 1, 2026. The Mumbai-based company has signed a perpetual license agreement with Novartis Pharma AG (Switzerland) to manufacture and market Galvus and Galvus combination brands, it said in a regulatory filing. "This deal is expected to further bolster Cipla's position in India as one of the top players in the diabetes category," it added. The agreement is subject to satisfaction of certain conditions precedent, the drug firm said. Galvus is one of the leading brands in the Dipeptidyl Peptidase-4 (DPP4) space and am

Hence then, the article about cipla inks licensing pact with novartis to manufacture mkt diabetes drug was published today ( Monday 10/04/2023 - 06:33 PM ) and is available on Business Standard ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Cipla inks licensing pact with Novartis to manufacture, mkt diabetes drug )

Also on site :

• Sequential™ Raises $3.5M to Build AI-Powered Discovery Platform for Multi-Omic Testing and Next-Generation Skin Health Ingredients
• Shoplazza Adopts Agentic Commerce Architecture to Power AI-Driven E-commerce Operations
• Doceree Builds Strategic Growth Team with Paresh Rajpurohit and Andreas Tsitsos, Accelerates M&A Focus